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tuberculin skin test (tSt) and ifn-γ release assays are currently used to detect Mycobacterium 
tuberculosis (Mtb) infection but none of them differentiate active from latent infection (LTBI). Since 
improved tests to diagnose Mtb infection are required, we studied the immune response to Mtb latency 
antigen Rv2626c in individuals exposed to the bacteria during different periods. Tuberculosis patients 
(TB), TB close contacts (CC: subjects exposed to Mtb for less than three months) and healthcare workers 
(HW: individuals exposed to Mtb at least two years) were recruited and QuantiFERON (QFT) assay, TST 
and ifn-γ secretion to Rv2626c were analyzed. Twenty-two percent of the individuals assessed had 
discordant results between QFT and TST tests. Furthermore, QFT negative and QFT positive individuals 
produced differential levels of IFN-γ against Rv2626c, in direct association with their exposure period 
to Mtb. Actually, 91% of CC QFT negative subjects secreted low levels of IFN-γ to Rv2626c, whereas 
43% of HW QFT negative people produced elevated IFN-γ amounts against Rv2626c. Conversely, 69% 
of CC QFT positive subjects didn´t produce IFN-γ to Rv2626c. Interestingly, a similar pattern of IgG 
anti-Rv2626c plasma levels was observed. Therefore, determination of IFN-γ and igG levels against the 
dormancy antigen Rv2626c allows to identify established LTBI.
Tuberculosis (TB) is the leading cause of decease by a single infectious agent and one of the top 10 causes of death 
worldwide. In 2018, the World Health Organization estimated 10 million new cases and 1.45 million deaths1. 
Furthermore, 1.7 billion people are considered latently infected with Mycobacterium tuberculosis (Mtb)1, repre-
senting a vast reservoir of the bacteria. Thus, there is an urgent need for developing rapid methods to detect Mtb 
infection. Tuberculin skin test (TST) is a commonly used screening method for Mtb infection2. However, TST 
displays a limited specificity and cannot distinguish active from latent TB infection3. Additionally, TB blood tests 
or interferon-gamma release assays (IGRAs) are other type of methods for detection of Mtb infection. Current 
IGRAs employ ESAT-6 and CFP-10, two antigens encoded in the region of difference 1 locus present in both Mtb 
and in M. bovis genomes4. Importantly, these antigens are missing in Bacillus Calmette-Guerin (BCG) vaccine 
1Instituto de Química Biológica, Facultad de Ciencias Exactas y Naturales (IQUIBICEN), Universidad de Buenos 
Aires (UBA)-CONICET, Intendente Güiraldes 2160, Pabellón II, 4° piso, Ciudad Universitaria (C1428EGA), Buenos 
Aires, Argentina. 2Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, UBA, Intendente 
Güiraldes 2160, Pabellón II, 4° piso, Ciudad Universitaria (C1428EGA), Buenos Aires, Argentina. 3Hospital General 
de Agudos Parmenio Piñero, Av. Varela 1301, (C1406EKZ), Buenos Aires, Argentina. 4División Tisioneumonología 
Hospital F.J. Muñiz, Uspallata 2272, (C1282AEN), Buenos Aires, Argentina. 5Centre de Recherche en Cancérologie 
de Marseille (CRCM), INSERM U1068, CNRS UMR 7258, Aix-Marseille Université and Institut Paoli-Calmettes, Parc 
Scientifique et Technologique de Luminy, Marseille, France. 6These authors contributed equally: Nicolás O. Amiano 
and María P. Morelli. ✉e-mail: vgarcia@qb.fcen.uba.ar
open
2Scientific RepoRtS |         (2020) 10:7472  | https://doi.org/10.1038/s41598-020-64428-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
and most environmental mycobacteria, which makes IGRAs more specific than TST4. However, both assays only 
detect individuals who has been infected with Mtb, but they do not differentiate between latent and active Mtb 
infection5,6. Therefore, the use of other distinctive Mtb antigens in blood tests is urgently required7.
During dormancy, the bacilli are contained in granulomas due to the active role of the immune system and 
the deprivation of nutrients and oxygen8. Hypoxia adaptation of the bacteria includes the expression of different 
proteins encoded in the DosR regulon9, which enables Mtb to successfully shift between aerobic and non-aerobic 
conditions10. Although the exact functions of numerous latency proteins still remain unknown, several of them 
have been analyzed as potential diagnostic markers11. Previously, we reported that the immune response to the 
Mtb dormancy antigen Rv2626c, differentiates latently infected BCG-vaccinated individuals from TB patients and 
healthy donors. Our findings demonstrated that specific epitopes from Rv2626c induced the secretion of signifi-
cant amounts of IFN-γ in latently infected individuals (LTBI) in sharp contrast to non-infected individuals12. In 
the present work, we investigated the effect of the exposure time to Mtb on the human immune response against 
Rv2626c antigen. Furthermore, besides the analysis of IFN-γ production against Rv2626c, we investigated the 
specific IgG plasma levels to this antigen.
Altogether, our results demonstrate that both IFN-γ and IgG responses against Rv2626c allow discriminating 
subjects with established latent Mtb infection from individuals recently exposed to the pathogen. These findings 
might represent an advantageous tool for the improvement of established LTBI diagnosis.
Results
Eighty-three close contacts (CC) of TB patients, 114 healthcare workers (HW) highly exposed to Mtb and 42 sub-
jects with active TB were studied. Age, sex, TST and QuantiFERON-TB Gold Plus kit (QFT) results are shown in 
Table 1. Briefly, CC comprised subjects who had lived or worked with recently diagnosed pulmonary TB patients 
for less than three months during 6 or more hours each day; HW included physicians and nurses who had worked 
at Hospital areas where TB patients were confined at least for two years; TB patients were subjects diagnosed with 
active disease (90% of them displayed acid-fast bacilli (AFB) smear-positive sputum).
Comparison of QuantiFERON-TB gold plus kit and TST results. We initially analyzed the levels of 
IFN-γ produced by CC, HW and TB patients by using the QuantiFERON-TB Gold Plus kit (QFT). In addition, 
we recorded the skin induration after TST administration by trained personnel. Our results showed that CC QFT 
positive individuals secreted significant higher levels of IFN-γ than HW QFT positive subjects (Fig. 1a). In con-
trast, no differences in the skin induration were detected between CC TST positive and HW TST positive groups 
(Fig. 1b). These results suggest that the IFN-γ response induced against QFT antigens (ESAT-6 and CFP-10) 
fluctuates according to the exposure time of subject to Mtb, whereas the delayed hypersensitivity to tuberculin is 
independent of the exposure time of the individual to the pathogen.
Next, we analyzed the correlation between the QFT and TST results from 167 out of 239 individuals that 
participated in the study. We observed that 54% of the subjects displayed negative results for both tests (double 
negative individuals) (Skin induration < 10 mm and [IFN-γ]QFT < 0.35 IU/mL) whereas 24% of the individuals 
presented positive results for both assays (double positive persons) (Fig. 1c). In addition, we also detected an 
important discrepancy between the two assays: 17% of the individuals displayed negative TST but positive QFT, 
whereas 5% of the subjects presented negative results for QFT but positive TST (Percent  Discordant = 22%). The 
analysis of multivariate categorical data using Cohen’s kappa coefficient (κ) showed 78% of coincident results for 
both tests (kappa = 0.530; Standard Error (SE) of kappa = 0.067). Considering that κ < 0.60 indicates a moderate 
agreement among the raters12, the discordant findings between QFT and TST suggest that the diagnosis of LTBI 
(traditionally determined by QFT positive and / or TST positive results in the absence of TB disease) needs to be 
improved.
Therefore, since we previously demonstrated that Mtb dormancy antigen Rv2626c differentiates latently 
infected BCG-vaccinated individuals13, we then assayed the correlation between QFT or TST results and the data 
obtained with a homemade Rv2626c IGRA. Briefly, we stimulated whole blood from 205 individuals (including 
CC, HW and TB patients) with Mtb Rv2626c antigen and 24 h after, IFN-γ production was determined by a 
commercial ELISA kit (BioLegend, USA). QFT assay was also performed in the same subjects. To analyze the 
Study Subjects Characteristic
Group 1: Close Contacts 
(CC) (N = 83)
Group 2: Healthcare 
Workers (HW) (N = 114)
Group 3: Tuberculosis 
Patients (TB) (N = 42)
Age (years), median (range) 38 (18–77) 39 (23–64) 30 (18–74)
Sex
Male 35 (42) 50 (44) 33 (79)
Female 48 (58) 64 (56) 9 (21)
QFT
(+) 33 (40) 38 (33) 34 (81)
(−) 46 (55) 76 (67) 5 (12)
Indeterminate 4 (5) 0 (0) 3 (7)
TST
(+) 17 (25) 17 (22) 18 (75)
(−) 50 (75) 60 (78) 6 (25)
AFB in 
sputum smear
(+) -------- -------- 38 (90)
(−) -------- -------- 4 (10)
Table 1. Population characteristics. Note: Values were expressed as number (percentage). AFB: Acid-Fast 
Baclli.
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correlation between Rv2626c IGRA and TST, we compared the results obtained with 118 individuals tested for 
both assays. Figure 2a shows that the established cut-off threshold for the Rv2626c IGRA was 0.45 IUIFN-γ/mL 
(Sensitivity = 78.95%; Specificity = 83.02%) as defined by a ROC analysis (Fig. 3c), whereas the QFT cut-off 
was 0.35 IUIFN-γ/mL according to the manufacturer. The TST cut-off was 10 mm according to local guidelines 
(Fig. 2b). Then, we first analyzed the correlation between QTF and Rv2626c IGRA results. Our results indicated 
that 34% of the studied people displayed negative results for both tests, and 21% of them exhibited double pos-
itive results (Percent Concordant = 55%). Moreover, by analyzing the data using the Cohen´s Kappa statistic 
Figure 1. QFT and TST analyses. (a) IFN-γ levels as measured by QFT. The levels of IFN-γ were assayed in 
whole blood from CC and HW QFT positive individuals and TB patients participating in the study by using the 
QFT kit. IFN-γ levels are expressed as IU/mL (IUIFN-γ/mL = IUIFN-γ/mL detected in TB1 or TB2 antigen tube – 
IUIFN-γ/mL measured in Nil tube). (b) Diameter of induration as measured by the Tuberculin Skin Test (TST). 
Purified protein derivative (PPD) was administered and 48–72 h after the injection, the skin test reaction was 
measured as mm of the induration. Mean ± SEM for each group of subjects is shown. **P < 0.01. P-values were 
calculated by Kruskal-Wallis test and Dunn’s multiple comparisons post-test for unpaired samples. Each symbol 
represents an individual. (c) Scatter plot of IFN-γ levels (as measured by QFT) and diameter of induration (as 
measured by TST). IFN-γ levels were assayed in whole blood using the QFT kit and were expressed as IU/mL. 
The skin test reaction was measured as mm of the induration after 48–72 h of PPD injection. The vertical dotted 
line represents the TST cut-off (10 mm); the horizontal dotted line indicates the QFT cut-off (0.35 IUIFN-γ/
mL). Percent Concordant = 78%; Percent Discordant = 22%. Kappa = 0.530. SE of kappa = 0.067. Moderate 
agreement.
Figure 2. (a) Scatter plot of IFN-γ levels as measured by QFT and by Rv2626c IGRA. IFN-γ levels in whole 
blood of participants were measured by using the QFT kit and the Rv2626c IGRA assay. The vertical dotted 
line represents the Rv2626c IGRA cut-off (0.45 IUIFN-γ/mL); the horizontal dotted line indicates the QFT cut-
off (0.35 IUIFN-γ/mL). Percent Concordant = 55%; Percent Discordant = 45%. Kappa = 0.106. SE of kappa = 
0.066. Slight agreement. (b) Scatter plot of mm of induration measured by TST and IFN-γ levels measured by 
the Rv2626c IGRA. IFN-γ levels in whole blood of participants were measured by using the Rv2626c IGRA 
assay. The vertical dotted line represents the Rv2626c IGRA cut-off (0.45 IUIFN-γ/mL). The skin test reaction was 
measured as mm of the induration after 48–72 h of PPD injection. The vertical dotted line represents the TST 
cut-off (10 mm). Percent Concordant = 61%; Percent Discordant = 39%. Kappa = 0.152. SE of kappa = 0.092. 
Slight agreement.
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coefficient, a slight agreement was detected (kappa = 0.106; SE of kappa = 0.066). Next, we examined the cor-
relation between the TST results and the Rv2626c IGRA data. We observed that 45% of the subjects analyzed 
presented negative results for both tests, and 16% showed double positive results (Percent Concordant = 61%). 
Moreover, the analyses using the Cohen´s Kappa statistic coefficient displayed a slight agreement (kappa = 0.152; 
SE of kappa = 0.092). Therefore, considering the weak concordance detected by analyzing the results of the avail-
able assays and our homemade IGRA, we hypothesized the existence of different responses to Rv2626c antigen 
from individuals comprised within each group (CC, HW y TB). Since our homemade Rv2626c assay measures 
IFN-γ by ELISA like QFT kit does, we next classified CC and HW according to QFT.
Analysis of ifn-γ responses to Rv2626c latency antigen in people highly exposed to M. tubercu-
losis. We have previously demonstrated that the dormancy antigen Rv2626c discriminates LTBI from healthy 
people and TB patients13. Briefly, subjects with positive QFT and TST results and no clinical or radiological evi-
dence of active TB were classified as LTBI, without considering the exposure period to Mtb. In the present work, 
we confirmed those previous findings showing that non TB QFT positive individuals produced significant higher 
levels of IFN-γ against Rv2626c than QFT negative subjects and TB patients (Fig. 3a). To further investigate the 
ability of this Mtb dormancy antigen to differentiate latently infected people, in the present work we consid-
ered the exposure time of each subject to the pathogen. Interestingly, we observed significantly different IFN-γ 
responses to Rv2626c between QFT negative and QFT positive individuals. Remarkably, we could establish that 
those differences were related to the exposure period of the individual to Mtb (Fig. 3b). In fact, 69% of CC QFT 
positive individuals (subjects commonly identified as LTBI) did not secrete IFN-γ in response to the specific Mtb 
latency antigen Rv2626c (Fig. 3b). On the other hand, 43% of HW QFT negative subjects (individuals that were 
not infected with Mtb according to QFT) responded to Rv2626c, as indicated by the levels of IFN-γ produced 
against the antigen (Fig. 3b). Furthermore, 79% of HW QFT positive subjects secreted elevated levels of IFN-γ 
when their blood´s cells were cultured with the latency antigen Rv2626c (Fig. 3b). Interestingly, and in contrast 
with these findings, stimulation of blood from TB patients and HW QFT positive individuals with HspX, another 
Mtb specific antigen, induced a significant IFN-γ production from both groups of subjects, but no differences 
could be detected between active and latent infected groups (data not shown). Therefore, our findings reflect 
that once Mtb enters the host, the pathogen requires a period of time to establish the dormancy state and secrete 
antigens like Rv2626c.
In view of our results, and to evaluate the potential use of Rv2626c to discriminate individuals with established 
latency from non - LTBI subjects, we performed a ROC analysis for IFN-γ responses. From those studies, sig-
nificant results were obtained (AUC = 0.8258; P < 0.0001; 95% CI: 0.7348–0.9169), demonstrating that Rv2626c 
allows differentiating LTBI individuals from other subjects exposed to Mtb, either infected or not infected (cut-off 
= 0.45 IUIFN-γ/mL; Sensitivity = 78.95%; Specificity = 83.02%).
As mentioned above an important number of HW QFT negative subjects (43%) displayed IFN-γ responses to 
Rv2626c antigen (Fig. 3b), indicating that many individuals with established Mtb latency infection (LTBI) could 
not be differentiated by QFT.
Figure 3. Production of IFN-γ against Rv2626c in whole blood from individuals highly exposed to 
Mycobacterium tuberculosis. (a,b) Whole blood was incubated with Rv2626c antigen (2.5 μg/mL) for 24 h. 
Afterwards, plasma samples were collected and IFN-γ production was evaluated by ELISA. The IFN-γ levels 
are expressed as IU/mL (IUIFN-γ/mL = IUIFN-γ/mL measured in Rv2626c tube – IUIFN-γ/mL measured in 
Negative control tube). Mean ± SEM for each group of subjects is shown. Each symbol represents an individual. 
*P < 0.05, ***P < 0.001, ****P < 0.0001. Kruskal-Wallis test and Dunn’s multiple comparisons post-test for 
unpaired samples. The horizontal dotted line indicates the Rv2626c IGRA cut-off (0.45 IUIFN-γ/mL). (c) ROC 
(Receiver Operating Characteristic) analysis for the IFN-γ responses to Rv2626c was performed to evaluate 
its potential use in discriminating LTBI (HW QFT positive) from other Mtb exposed individuals (CC QFT 
negative and positive and TB). AUC = 0.8258; P < 0.0001; 95% CI: 0.7348–0.9169.
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IgG responses to Rv262c antigen in close contacts, healthcare workers and TB patients. We 
also evaluated the levels of IgG against Rv2626c antigen in plasma from individuals included in the study groups. 
Thus, using a homemade ELISA, we measured the levels of IgG anti-Rv2626c in plasma from CC, HW and TB 
patients. Interestingly, IgG anti-Rv2626c results showed the same trend than IFN-γ data. Accordingly, CC QFT 
negative, CC QFT positive individuals and TB patients displayed the lowest levels of IgG against Rv2626c. In 
contrast, HW QFT positive subjects presented the highest levels of IgG anti-Rv2626c (Fig. 4a). Moreover, HW 
QFT negative displayed significant higher levels of IgG against Rv2626c as compared to patients with active Mtb 
infection or CC QFT negative individuals (Fig. 4a). Actually, 54% of HW QFT negative people presented plasma 
IgG response to Rv2626c antigen (Fig. 4a), in accordance with our IFN-γ results (Fig. 3b). Furthermore, the ROC 
analysis for IgG responses to Rv2626c in plasma reinforced the potential of Rv2626c antigen for discriminating 
individuals with established Mtb latency infection from other non-LTBI individuals (Fig. 4b, AUC = 0.9186; 
P < 0.0001; 95% CI: 0.8358-1.001; cut-off = 10 ngIgG/mL; Sensitivity = 93.75%; Specificity = 81.08%).
Together, our present findings indicate that QFT fails to identify a significant number of LTBI individuals. 
Furthermore, we demonstrate that many QFT positive individuals do not respond to a specific dormancy Mtb 
antigen, impairing the confirmation of latent infection. In conclusion, either by using the Rv2626c IGRA or by 
measuring anti-Rv2626c IgG antibodies we were able to diagnose established Mtb latent infection.
Discussion
Twenty-eight years ago, the WHO issued a press release announcing that TB was a global emergency14. Although 
progress has been made since then, no country has eliminated TB and almost 2 billion persons are now latently 
infected with Mtb1. In order to achieve disease control, a reliable diagnostic method for latent infection is 
required. Currently, both TST and IGRAs are used for the diagnosis of Mtb infection. However, these tests do not 
discriminate active from latent infection and no gold standard for LTBI diagnosis is available15. Thus, improved 
assays to diagnose latent and active Mtb infection are immediately required. In line with this, we previously 
demonstrated that whole blood stimulation with Rv2626c allowed to differentiate QFT positive individuals from 
TB patients and healthy donors13. Recently, Singh et al. showed that peripheral blood mononuclear cell (PBMC) 
stimulation with Rv2626c induced 2% of CD4+IFN-γ+ T lymphocytes in TB patients but no response in healthy 
donors. However, the authors provided no information about TST and/or QFT results for the study subjects16. 
Besides, Prabhavathi et al. reported that cell stimulation with Rv2626c produced significant levels of IFN-γ 
against Rv2626c in QFT positive healthy household contacts whereas TB patients did not respond to this anti-
gen17. In contrast to our present study, Prabhavathi et al.´s work did not include QFT negative household contacts 
and QFT positive/negative HW individuals. Furthermore, QFT positive healthy household contacts comprised 
individuals exposed to Mtb for at least three months17. On the other hand, in a proof-of-principle study, Goletti 
et al. reported that cell stimulation with Rv2626c did not induce IFN-γ responses from subjects with recent or 
remote Mtb infection18. In contrast to our present data, Goletti et al.´s work included a limited number of indi-
viduals with only 4% of Latin American subjects18.
In the present work, we extended our previous studies to further investigate whether Rv2626c antigen might 
be used to identify subjects with established latent tuberculosis infection. Both TST positive and IGRA positive 
results might refer to an heterogeneous group of individuals: subjects who have subclinical disease; people with 
Figure 4. Antibody responses to Rv2626c antigen in plasma from individuals highly exposed to Mycobacterium 
tuberculosis. (a) Samples from CC, HW and TB patients were collected and total IgG responses were measured 
by ELISA. Each symbol represents the levels of anti-Rv2626c IgG per individual (ng/mL). Mean ± SEM for 
each group of subjects is shown. **P < 0.01, ****P < 0.0001. P-values were calculated by Kruskal-Wallis test 
and Dunn’s multiple comparisons post-test for unpaired samples. The horizontal dotted line indicates the IgG 
ELISA cut-off (10 ng/mL). (b) ROC (Receiver Operating Characteristic) analysis for IgG responses to Rv2626c 
was performed to evaluate its potential use in discriminating LTBI (HW QFT positive) from other Mtb exposed 
individuals (CC QFT positive and QFT negative and TB). AUC = 0.9186; P < 0.0001; 95% CI: 0,8358–1,001.
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persistent, lifelong infection and active immune control (“true” latent infection); those who temporarily contain 
Mtb infection but then develop active disease (caused by immunosuppression for example); persons who progress 
to primary active disease and individuals that could effectively clear the pathogen with development of detect-
able T cell mediated adaptive response (uninfected persons)8. Therefore, the existence of this wide spectrum of 
TST positive/IGRA positive individuals clearly reflects that QFT positive results do not indicate latent infection, 
especially in tuberculosis endemic countries. Therefore, besides ESAT-6 and CFP-10 QFT antigens, it urges to 
find new Mtb antigens, which might complement or improve current assays to diagnose both latent and active 
infections.
LTBI is related to a dormancy state of Mtb and various antigens up-regulated during latency have been 
proposed as potential diagnostic biomarkers. Accordingly, we have reported the immune-stimulatory role of 
Rv2626c, a highly expressed protein during hypoxic conditions. Although Rv2626c can be identified in culture 
filtrates and lysates of Mtb19, its role remains to be elucidated. Variable results using Rv2626c latency antigen were 
reported by others9,16–18,20, although the disparities could be related to differences in stimulation schemes, antigen 
concentrations, ethnic backgrounds and BCG vaccination history13.
In our present study 22% of the individuals assessed had discordant results between QFT and TST results. 
Moreover, a subpopulation of QFT negative individuals secreted significant IFN-γ levels against Rv2626c (90% 
HW exposed to Mtb for more than two years). On the other side, we observed that 43% of QFT positive non-TB 
subjects did not respond to Rv2626c stimulation (73% CC exposed to Mtb for less than three months).
Although the importance of humoral immunity in TB has been commonly neglected21, recent evidence 
indicated that B lymphocytes can modulate the host response to various intracellular pathogens including 
Mycobacterium spp22. In this regard, Coppola et al. reported that IgG levels against Rv1733c Mtb antigen corre-
lated with control of TB infection and progression, while other Mtb antigen-specific antibodies correlated with 
TB disease activity and bacillary loads23. Besides, it has been proposed that, since Mtb can change its physiological 
state during different stages of infection, showing a differential expression of immunogenic antigens, latent or 
active TB might be identified by specific antibody profiles24. Accordingly, in order to differentiate active TB from 
LTBI or controls, de Araujo et al. analyzed the specific IgG subclasses elicited in response to a set of mycobacterial 
antigens. Based on their findings, the authors suggested that antibodies subclasses would be differentially modu-
lated during Mtb infection24. In addition, the poor discriminatory power of current serodiagnostic tests in regions 
of endemicity has been reported25. This might be explained by a significant antibody response against some Mtb 
antigens in latently infected contacts, as well as TB patients, particularly in areas with high levels of exposure to 
Mtb25,26. Previously, two different groups measured high levels of circulating antibodies against Rv2626c in TB 
patients27,28. However, none of those studies included a significant number of LTBI QFT and/or TST positive 
subjects to support their findings. In the present work, we detected the highest levels of plasma anti-Rv2626c IgG 
in subjects with established latent infection, whereas the lowest amounts of these antibodies were measured in 
recently infected CC and TB patients (Fig. 4a). Interestingly, the pattern of plasma anti-Rv2626c IgG detected in 
the study groups was consistent with our data regarding IFN-γ secretion to Rv2626c.
Pollock et al. previously reported that QFT failed to detect LTBI among HW29. Thus, the authors suggested 
that QFT negative results should be interpreted with quite caution. Furthermore, Park et al. demonstrated impor-
tant fluctuations in the IGRAs results from high Mtb exposed HW tested during one year30. Those oscillations 
were related either to a poor reproducibility of the QFT assay or to a periodic secretion of antigens from Mtb. 
Our findings indicate that QFT fails to identify a significant number of Mtb infected individuals that display 
specific IFN-γ and IgG responses against Rv2626c. Together, our data demonstrate that subjects with established 
latent Mtb infection might be discriminated from individuals recently exposed to the pathogen by analyzing their 
immune responses to Rv2626c Mtb antigen. Therefore, considering previous published data and our present 
results we hypothesize that the use of a dormancy antigen such as Rv2626c could be an advantageous tool for the 
improvement of the diagnosis of established LTBI. An assay including this latency antigen would reduce false 
QFT negative results for individuals that have been long exposed to Mtb, allowing proving an established latency 
state in infected people.
Methods
Study subjects. For this study, individuals exposed to Mycobacterium tuberculosis (Mtb) during different 
periods or subjects infected with the bacteria were recruited. Therefore, the following groups of individuals were 
included: 1) Close contacts (CC): subjects who had lived or worked for less than three months, during 6 or more 
hours each day, with recently diagnosed pulmonary tuberculosis patients. 2) Healthcare workers (HW): physi-
cians and nurses who had worked at least two years at Hospital areas where tuberculosis patients were confined. 
3) Tuberculosis patients (TB): subjects diagnosed with active disease as evaluated at Dr. F. Muñiz or P. Piñero 
Hospitals (Buenos Aires, Argentina). Diagnosis was established based on clinical and radiological data together 
with culture-confirmation. None of the patients included in this study had displayed multidrug-resistant (MDR) 
or extremely drug resistant (XDR) tuberculosis. The participating tuberculosis patients had received less than one 
week of anti-TB therapy (rifampicin, pyrazinamide, ethambutol and isoniazid). Information regarding demo-
graphic data was obtained at the time of recruitment through a structured questionnaire. All participants pro-
vided written informed consent for sample collection and subsequent analysis. The protocols conducted through 
the present work were approved by the Ethical Committees of the Dr. F. Muñiz and the P. Piñero Hospitals. All 
methods were carried out in accordance with relevant guidelines and regulations.
Study inclusion and exclusion criteria. Inclusion criteria: a) adult (over 18 years old) men and women 
with active pulmonary TB and b) healthy volunteers with high level of exposure to Mtb (CC of TB patients and 
HW from Public Hospitals). All enrolled subjects in this study had been BCG-vaccinated. Mtb positive cultures 
were obtained for all TB patients included in this study.
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Exclusion criteria: a) HIV positive infection or positive serology for other viral (e.g., hepatitis A, B or C), or 
bacterial infections (e.g., leprosy, syphilis, etc); b) patients with diabetes, cancer, autoimmune diseases or other 
conditions that may affect the immune system of the individual; c) pregnant women and d) children. Among the 
population of TB patients, we excluded: a) patients with multidrug-resistant tuberculosis (MDR) infection or 
extremely drug resistant (XDR) tuberculosis and b) patients with more than seven consecutive days of anti-TB 
treatment.
tuberculin skin test. TST was administered by the medical staff according to the Mantoux procedure. 
Briefly, two tuberculin units (0.1 ml) of purified protein derivative (PPD, Instituto Nacional de Mirobiología Dr. 
Malbrán, Buenos Aires, Argentina) were injected by intradermal route into the inner surface of the forearm. The 
skin induration was measured (in mm) after 48–72 h by trained personnel. A positive TST was defined as an indu-
ration size ≥ 10 mm, according to National Guidelines31. In CC individuals, TST was performed immediately 
(less than 7 days) after tuberculosis diagnosis of the index case. Furthermore, in TB patients, TST was performed 
before the start of antibiotic treatment. In the case of HW, the TST assay was performed immediately after blood 
extraction for the QFT test.
QuantiFERON-TB Gold Plus (QFT) Assay. QFT (Qiagen, Germany, USA) test and data interpretation 
were performed according to the manufacturer´s instructions. QFT results were recorded positive if a single 
antigen tube (either TB1 or TB2) was ≥ 0.35 IU/mL as compared to the negative control (“Nil” tube). In CC 
subjects, QFT assay was performed immediately (less than 7 days) after tuberculosis diagnosis of the index case. 
Furthermore, in TB patients, QFT was performed before the start of antibiotic treatment.
Rv2626c antigen. Recombinant antigen Rv2626c was produced as previously described13. Briefly, the 
protein was expressed in Escherichia coli BL21 (DE3) pLysS and purified using a nickel nitrilotriacetic system 
(Ni-NTA Agarose, Qiagen, USA), following the manufacturer´s instructions. After purity control, the protein 
was concentrated using Amicon (Merck Millipore, USA) commercial columns and then Detoxi-Gel Endotoxin 
Removing Resin (Pierce, USA) were used to remove possible endotoxin traces.
Rv2626c interferon gamma release assay (Rv2626c IGRA). A new IGRA using Rv2626c as anti-
gen was developed for this work. The same blood sample obtained from each participant was used to perform 
Rv2626c IGRA and QFT. Rv2626c IGRA consists of the following two steps:
Whole blood stimulation. Heparinized whole blood (500 µL) was seeded in 5 mL sterile round-bottom polysty-
rene tubes with caps (Falcon, USA) and Rv2626c antigen (2.5 µg/mL), phytohaemagglutinin (PHA-P, 5 µg/mL, 
positive control, Sigma-Aldrich, USA) or HBSS buffer (negative control) were added and incubated for 16–24 h 
at 37 °C. Afterwards, plasmas were recovered to determine IFN-γ production by ELISA.
IFN-γ determination. The levels of IFN-γ were evaluated using a commercial ELISA kit (Human IFN-γ ELISA 
MAX Standard Kit, BioLegend, USA) following the manufacturer´s instructions. Data are shown as international 
units of IFN-γ per milliliter (IUIFN-γ/mL) after subtracting the negative control value.
ELISA to determine plasma anti-Rv2626c IgG. High binding ELISA plates were coated with recom-
binant Rv2626c at 2.5 μg/mL or different dilutions of a human IgG antibody standard (calibration curve; Vigam 
Liquid Inmunoglobulina Humana Normal). Plates were blocked with 2% skim milk in saline solution. Samples 
(plasma obtained from heparinized non-stimulated whole blood) were diluted 1:100 and run in duplicate. Then, 
a secondary antibody (biotin mouse anti-human IgG - BD Pharmingen, USA) was added. Plates were conse-
quently incubated for 1 h at 37 °C. High sensitivity streptavidin - horseradish peroxidase enzyme (Thermo Fisher 
Scientific, USA) was incorporated and 3, 3′5, 5′-tetramethylbenzidine (TMB) (Sigma-Aldrich, USA) substrate 
was added. Finally, sulfuric acid was incorporated to stop the enzyme reaction and plates were read at 450 nm. 
The results are expressed as ng/ml of IgG.
Statistical analysis. In all the graphs, each symbol represents an individual. Moreover, data were expressed 
as mean ± standard error of the mean (SEM). The Kruskal – Wallis (K-W) followed by Dunn’s multiple compar-
isons tests for unpaired and non-parametric samples were used to analyze differences between groups. Monte 
Carlo simulations for the chosen K-W methods resulted in a minimum group size of 15 for statistical power > 
0.8. Briefly, a K-W Rank Sum method was performed on simulated data and the resulting P-value was recorded. 
This process was repeated 10.000 times at each group size (N) evaluated, from 2 to 50. And we found that at 
N = 15, the proportion of P-values < 0.05 was greater than 0.8 (P = 0.81). Therefore, the results from K-W tests 
performed on data with similar distribution to that recorded by the experimenters and with group sizes larger 
than 15 have more than 80% probability of rejecting the null hypothesis on the K-W test.
Receiver operating characteristic (ROC) curve analysis was performed to analyze the predictive value of 
IFN-γ response to Rv2626c, or anti-Rv2626c IgG response, calculating the area under the curve (AUC) and the 
95% confidence interval (CI). Comparison between the diagnostic methods (QFT / TST, QFT/Rv2626c IGRA and 
TST/Rv2626c IGRA) was made using the Cohen’s Kappa Statistic test. Analyses were performed using GraphPad 
Prism 7.00 software. P < 0.05 was considered statistically significant.
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